Journal Article
. 2016 Jul;108(11).
doi: 10.1093/jnci/djw149.

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy

Richard Buus 1 Ivana Sestak 1 Ralf Kronenwett 1 Carsten Denkert 1 Peter Dubsky 1 Kristin Krappmann 1 Marsel Scheer 1 Christoph Petry 1 Jack Cuzick 1 Mitch Dowsett 1 
Affiliations
  • PMID: 27400969
  •     18 References
  •     57 citations

Abstract

Background: Estimating distant recurrence (DR) risk among women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative early breast cancer helps decisions on using adjuvant chemotherapy. The 21-gene Oncotype DX recurrence score (RS) is widely used for this. EndoPredict (EPclin) is an alternative test combining prognostic information from an eight-gene signature (EP score) with tumor size and nodal status. We compared the prognostic information provided by RS and EPclin for 10-year DR risk.

Methods: We used likelihood ratio χ² and Kaplan-Meier survival analyses to compare prognostic information provided by EP, EPclin, RS, and the clinical treatment score (CTS) of clinicopathologic parameters in 928 patients with ER+ disease treated with five years' anastrozole or tamoxifen. Comparisons were made for early (0-5 years) and late (5-10 years) DR according to nodal status. All statistical tests were two-sided.

Results: In the overall population, EP and EPclin provided substantially more prognostic information than RS (LRχ(2): EP = 49.3; LRχ(2): EPclin = 139.3; LRχ(2): RS = 29.1), with greater differences in late DR and in node-positive patients. EP and EPclin remained statistically significantly prognostic when adjusted for RS (ΔLRχ(2): EP+RS vs RS = 20.2; ΔLRχ(2): EPclin+RS vs RS = 113.8). Using predefined cut-offs, EPclin and RS identified 58.8% and 61.7% patients as low risk, with hazard ratios for non-low vs low risk of 5.99 (95% confidence interval [CI] = 3.94 to 9.11) and 2.73 (95% CI = 1.91 to 3.89), respectively.

Conclusions: EP and EPclin were highly prognostic for DR in endocrine-treated patients with ER+, HER2-negative disease. EPclin provided more prognostic information than RS. This was partly but not entirely because of EPclin integrating molecular data with nodal status and tumor size.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick, Ivana Sestak, +5 authors, ATAC/LATTE investigators.
Lancet Oncol, 2010 Nov 23; 11(12). PMID: 21087898
Highly Cited.
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay.
Carsten Denkert, Ralf Kronenwett, +23 authors, Manfred Dietel.
Virchows Arch, 2012 Mar 01; 460(3). PMID: 22371223    Free PMC article.
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Jack Cuzick, Mitch Dowsett, +10 authors, John F Forbes.
J Clin Oncol, 2011 Oct 13; 29(32). PMID: 21990413
Highly Cited.
Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
P-L Jerevall, X-J Ma, +9 authors, O Stål.
Br J Cancer, 2011 May 12; 104(11). PMID: 21559019    Free PMC article.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer.
Mitch Dowsett, Ivana Sestak, +6 authors, Jack Cuzick.
Clin Cancer Res, 2015 Jun 17; 21(12). PMID: 26078431
Forest plots and the interpretation of subgroups.
Jack Cuzick.
Lancet, 2005 Apr 13; 365(9467). PMID: 15823379
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Dennis C Sgroi, Ivana Sestak, +9 authors, Mitch Dowsett.
Lancet Oncol, 2013 Sep 17; 14(11). PMID: 24035531    Free PMC article.
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
P Dubsky, J C Brase, +18 authors, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Br J Cancer, 2013 Oct 26; 109(12). PMID: 24157828    Free PMC article.
Highly Cited.
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
Gong Tang, Jack Cuzick, +6 authors, Norman Wolmark.
J Clin Oncol, 2011 Oct 20; 29(33). PMID: 22010013    Free PMC article.
International Web-based consultation on priorities for translational breast cancer research.
Mitch Dowsett, Aron Goldhirsch, +3 authors, Giuseppe Viale.
Breast Cancer Res, 2007 Nov 24; 9(6). PMID: 18034879    Free PMC article.
Factors predicting late recurrence for estrogen receptor-positive breast cancer.
Ivana Sestak, Mitch Dowsett, +4 authors, Jack Cuzick.
J Natl Cancer Inst, 2013 Sep 14; 105(19). PMID: 24029245    Free PMC article.
Highly Cited.
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2015 Jul 28; 386(10001). PMID: 26211827
Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Review.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
Review.
High neuronatin (NNAT) expression is associated with poor outcome in breast cancer.
Norbert Nass, Sarah Walter, +5 authors, Thomas Kalinski.
Virchows Arch, 2017 May 26; 471(1). PMID: 28540450
Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?
Ann H Partridge, Lisa A Carey.
Clin Cancer Res, 2017 Jun 03; 23(11). PMID: 28572255    Free PMC article.
Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study.
Mahesh Iddawela, Oscar Rueda, +4 authors, Carlos Caldas.
BMC Genomics, 2017 Jul 13; 18(1). PMID: 28697743    Free PMC article.
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).
Michael Untch, Jens Huober, +18 authors, Cornelia Liedtke.
Geburtshilfe Frauenheilkd, 2017 Aug 05; 77(6). PMID: 28769126    Free PMC article.
Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.
Dara B Bracken-Clarke, Mairi W Lucas, Michaela J Higgins.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785180    Free PMC article.
Review.
Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy.
Ivana Sestak.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785181    Free PMC article.
Review.
MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.
Andreas Bösl, Andreas Spitzmüller, +3 authors, Felix Offner.
PLoS One, 2017 Aug 30; 12(8). PMID: 28850621    Free PMC article.
Are online prediction tools a valid alternative to genomic profiling in the context of systemic treatment of ER-positive breast cancer?
Umar Wazir, Kinan Mokbel, Amtul Carmichael, Kefah Mokbel.
Cell Mol Biol Lett, 2017 Sep 08; 22. PMID: 28878809    Free PMC article.
Review.
Analytical validation of a 12-gene molecular test for the prediction of distant recurrence in breast cancer.
M Bryan Warf, Saradha Rajamani, +6 authors, Benjamin B Roa.
Future Sci OA, 2017 Sep 09; 3(3). PMID: 28884016    Free PMC article.
Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
Alberto Peláez-García, Laura Yébenes, +9 authors, David Hardisson.
PLoS One, 2017 Sep 09; 12(9). PMID: 28886093    Free PMC article.
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
M C U Cheang, J M Bliss, +13 authors, PathIES Sub-Committee.
Breast Cancer Res Treat, 2017 Nov 28; 168(1). PMID: 29177605    Free PMC article.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, +9 authors, Mitch Dowsett.
JAMA Oncol, 2018 Feb 17; 4(4). PMID: 29450494    Free PMC article.
Highly Cited.
Spotlight on the utility of the Oncotype DX® breast cancer assay.
Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann.
Int J Womens Health, 2018 Mar 06; 10. PMID: 29503586    Free PMC article.
Review.
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Mitch Dowsett, Ivana Sestak, +5 authors, Jack Cuzick.
J Clin Oncol, 2018 Apr 21; 36(19). PMID: 29676944    Free PMC article.
Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
Irene E G van Hellemond, Sandra M E Geurts, Vivianne C G Tjan-Heijnen.
Curr Treat Options Oncol, 2018 Apr 29; 19(5). PMID: 29704066    Free PMC article.
Review.
Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.
Yun Yeong Kim, Se Jeong Oh, +2 authors, Heung Kyu Park.
PLoS One, 2018 Jul 07; 13(7). PMID: 29979736    Free PMC article.
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians.
Paul Gass, Michael Untch, +18 authors, Naiba Nabieva.
Geburtshilfe Frauenheilkd, 2018 Jul 31; 78(7). PMID: 30057427    Free PMC article.
Genomic Testing in the Management of Early-Stage Breast Cancer.
Sima Ehsani, Kari Braun Wisinski.
J Clin Outcomes Manag, 2017 May 01; 24(5). PMID: 30158821    Free PMC article.
Predictive markers of endocrine response in breast cancer.
Duniya Mosly, Arran Turnbull, +2 authors, Simon Langdon.
World J Exp Med, 2018 Sep 08; 8(1). PMID: 30191138    Free PMC article.
[Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer].
Marciana Nona Duma.
Strahlenther Onkol, 2018 Sep 22; 194(11). PMID: 30238419
Prognosis and endocrine therapy selection for patients with low hormone receptor-positive breast cancer following neoadjuvant chemotherapy: A retrospective study of 570 patients in China.
Yuqin Ding, Kaijing Ding, +6 authors, Xiaowen Ding.
Oncol Lett, 2019 Dec 07; 18(6). PMID: 31807179    Free PMC article.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
Review.
Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels.
Mark Francis Evans, Pamela Mary Vacek, +3 authors, Donald Lee Weaver.
J Cell Biochem, 2019 Oct 09; 121(2). PMID: 31595577    Free PMC article.
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence.
Fabio Conforti, Laura Pala, +12 authors, Aron Goldhirsch.
Breast Cancer Res, 2020 Jan 01; 21(1). PMID: 31888717    Free PMC article.
Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT2-Profiler Multiplex RT-PCR.
Verena Schildgen, Mathias Warm, Michael Brockmann, Oliver Schildgen.
Sci Rep, 2020 Jan 01; 9(1). PMID: 31889145    Free PMC article.
Research-based PAM50 signature and long-term breast cancer survival.
Minya Pu, Karen Messer, +10 authors, Loki Natarajan.
Breast Cancer Res Treat, 2019 Sep 23; 179(1). PMID: 31542876    Free PMC article.
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Hatem Soliman, Susanne Wagner, +9 authors, William Gradishar.
Ann Surg Oncol, 2020 Jan 08; 27(3). PMID: 31907749    Free PMC article.
Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients.
Thorsten Heilmann, Florian Vondung, +11 authors, Anna Trauzold.
J Mol Med (Berl), 2019 Jun 12; 97(8). PMID: 31183506
miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study.
Loki Natarajan, Minya Pu, +10 authors, Karen Messer.
Cancer Epidemiol Biomarkers Prev, 2019 Jun 13; 28(9). PMID: 31186261    Free PMC article.
The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
Arian Lundberg, Linda S Lindström, +8 authors, Nicholas P Tobin.
Breast Cancer Res, 2019 Mar 02; 21(1). PMID: 30819233    Free PMC article.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Review.
DEAD-box RNA Helicase 39 Promotes Invasiveness and Chemoresistance of ER-positive Breast Cancer.
Xiudi Wang, Peipei Li, +4 authors, Jiajin Lin.
J Cancer, 2020 Mar 21; 11(7). PMID: 32194796    Free PMC article.
Change in therapeutic management after the EndoPredict assay in a prospective decision impact study of Mexican premenopausal breast cancer patients.
Cynthia Villarreal-Garza, Edna Anakarenn Lopez-Martinez, +9 authors, Veronica Bautista-Piña.
PLoS One, 2020 Mar 12; 15(3). PMID: 32160201    Free PMC article.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations.
Ryan J O Dowling, Kevin Kalinsky, +29 authors, Pamela J Goodwin.
JNCI Cancer Spectr, 2020 Apr 28; 3(4). PMID: 32337479    Free PMC article.
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer.
K Almstedt, S Mendoza, +9 authors, M Schmidt.
Breast Cancer Res Treat, 2020 May 22; 182(1). PMID: 32436145    Free PMC article.
RDGN-based predictive model for the prognosis of breast cancer.
Bing Dong, Ming Yi, +2 authors, Kongming Wu.
Exp Hematol Oncol, 2020 Jun 19; 9. PMID: 32550045    Free PMC article.
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).
Frédérique Penault-Llorca, Fabrice Kwiatkowski, +18 authors, Suzette Delaloge.
Breast, 2019 Dec 04; 49. PMID: 31790959    Free PMC article.
Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay.
Hatem Soliman, Darl D Flake, +10 authors, William Gradishar.
JCO Precis Oncol, 2020 Sep 12; 3. PMID: 32914026    Free PMC article.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
Review.
Prognosis vs Treatment Interaction.
Jack Cuzick.
JNCI Cancer Spectr, 2018 Apr 28; 2(1). PMID: 31360838    Free PMC article.
Comparison of long-term results between radiotherapy after breast-conserving surgery and postmastectomy radiotherapy in stage T1-2N1M0 breast cancer.
Xiao-Wen Lan, Ge Wen, +5 authors, Xiao-Bo Huang.
Cancer Manag Res, 2019 Aug 03; 11. PMID: 31372049    Free PMC article.
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Mi Jeong Kwon, Jeong Eon Lee, +12 authors, Young Kee Shin.
Front Oncol, 2019 Aug 14; 9. PMID: 31404265    Free PMC article.
Genomic Signatures in Luminal Breast Cancer.
Julian Puppe, Tabea Seifert, +3 authors, Wolfram Malter.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982645    Free PMC article.
Review.
Individualized Chemotherapy Benefit Prediction by EndoPredict in Patients With Early Breast Cancer in an Indian Cohort.
S P Somashekhar, Shabber Zaveri, +4 authors, Charu Bahl.
JCO Glob Oncol, 2020 Sep 09; 6. PMID: 32897733    Free PMC article.
Transcriptome-wide analysis and modelling of prognostic alternative splicing signatures in invasive breast cancer: a prospective clinical study.
Linbang Wang, Yuanyuan Wang, +8 authors, Jinxiang Tan.
Sci Rep, 2020 Oct 07; 10(1). PMID: 33020551    Free PMC article.
A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer.
Caijin Lin, Jiayi Wu, +8 authors, Li Zhu.
Front Oncol, 2020 Oct 13; 10. PMID: 33042787    Free PMC article.
First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.
Johannes Ettl, Sophie-Isabelle Anders, +5 authors, Marion Kiechle.
Arch Gynecol Obstet, 2020 Sep 10; 302(6). PMID: 32902674    Free PMC article.
Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX.
Aditya K Sengupta, Aparna Gunda, +4 authors, Manjiri M Bakre.
Cancer Med, 2020 Oct 08; 9(21). PMID: 33027559    Free PMC article.
SEOM clinical guidelines in early stage breast cancer (2018).
F Ayala de la Peña, R Andrés, +7 authors, E Ciruelos.
Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30443868    Free PMC article.
[Update of the German S3 breast cancer guideline : What is new for pathologists?]
A Lebeau, C Denkert, +2 authors, A Wöckel.
Pathologe, 2019 Mar 09; 40(2). PMID: 30847505
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
Ivana Sestak, Miguel Martín, +12 authors, Michael Gnant.
Breast Cancer Res Treat, 2019 May 02; 176(2). PMID: 31041683    Free PMC article.
A 23-gene prognostic classifier for prediction of recurrence and survival for Asian breast cancer patients.
Ting-Hao Chen, Jian-Ying Chiu, Kuan-Hui Shih.
Biosci Rep, 2020 Nov 24; 40(12). PMID: 33226082    Free PMC article.
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients.
Camille Moreau-Bachelard, Loïc Campion, +6 authors, Jean-Sébastien Frénel.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33322473    Free PMC article.
The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Wakako Tajiri, Hideki Ijichi, +8 authors, Eriko Tokunaga.
Breast Cancer, 2020 Jul 01; 28(1). PMID: 32601800    Free PMC article.